The latest move at Celcuity (CELC) is not about trial data or sales figures. The firm recently added David W. Gryska to its board and key committees.
Celcuity’s share price has been under pressure recently, with the stock down 27.04% over the past 30 days and 36.91% over 90 days. However, the 1-year total shareholder return of 37.19% and the more than 7x 3-year total shareholder return point to longer term momentum. This contrasts with the current pullback and reflects shifting views on both growth potential and risk following the REVTORPYK launch and a new board appointment.
Scan how Celcuity compares with other potential oncology opportunities by reviewing the hand-picked 32 healthcare AI stocks that combine healthcare exposure with AI-driven pipelines and platforms.
Bulls see REVTORPYK and a seasoned finance hire as fuel for the next phase at Celcuity. Bears point to losses and recent share price pressure. Which story fits the current valuation?
Most Popular Narrative: 58% Undervalued
On the latest numbers, Celcuity closed at $67.87 while the most followed narrative pegs fair value near $161.09. This creates a wide gap that hinges on how gedatolisib plays out in breast cancer and beyond.
Management estimates a US$5b to US$6b addressable market in second line HR positive, HER2 negative advanced breast cancer and has indicated potential peak revenue for gedatolisib of US$2.5b to US$3b in this setting. If partially realized, this would be a key driver of top line growth over time.
See why 5 investors see Celcuity as 58% undervalued.
Result: Fair Value of $161.09 (UNDERVALUED)
Still, the Celcuity story depends on clinical and regulatory execution, and any setback on VIKTORIA trials or FDA timing could quickly challenge today’s optimistic narrative.
Find out about the key risks to this Celcuity narrative.
Next Steps
Sentiment around Celcuity is split, which is exactly why it helps to move fast, review the numbers in context, and decide where you stand after weighing 3 key rewards and 3 important warning signs.
Looking for more Celcuity-like investment ideas?
If Celcuity sparks your interest, do not stop here. Use the Simply Wall Street Screener to uncover fresh opportunities that match your style before others do.
- Target potential mispricings by scanning a curated 27 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their underlying business strength.
- Build a steadier income stream by reviewing a focused set of 8 dividend fortresses that offer higher yields with an emphasis on durability.
- Sleep easier through market swings by concentrating on a 31 resilient stocks with low risk scores that emphasizes resilient balance sheets and lower overall risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com